Kirsty Hicks

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

Valerie J. Ludbrook, Kirsty Hicks, Kate Hanrott et al. · British Journal of Dermatology · 2016 · 80 citations

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

Lesley Kahl, Jessal J. Patel, Mark Layton et al. · Lupus · 2016 · 66 citations

Immunodeficiencies, Immunology, Pharmacotherapy +18

CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6⁺ cells in an experimental suction blister

Gerben Bouma, Stefano Zamuner, Kirsty Hicks et al. · British Journal of Clinical Pharmacology · 2017 · 44 citations · Full text

Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers

Jianfeng Xu, Frank Gray, Alex Henderson et al. · Clinical Pharmacology in Drug Development · 2013 · 34 citations

Molecular Pharmacology, Hypertension, Heart Rate +14

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

John D. Isaacs, Sarah Brockbank, Ayako Wakatsuki Pedersen et al. · Scientific Data · 2022 · 23 citations · Full text